KAHRAMAN, S. Et Al. 2023. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer. Future oncology (London, England) , vol.19, no.10 , 727-736.

KAHRAMAN, S., Erul, E., Seyyar, M., GÜMÜŞAY, Ö., Bayram, E., Demirel, B. C., ... Acar, O.(2023). Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer. Future oncology (London, England) , vol.19, no.10, 727-736.

KAHRAMAN, SEDA Et Al. "Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer," Future oncology (London, England) , vol.19, no.10, 727-736, 2023

KAHRAMAN, SEDA Et Al. "Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer." Future oncology (London, England) , vol.19, no.10, pp.727-736, 2023

KAHRAMAN, S. Et Al. (2023) . "Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer." Future oncology (London, England) , vol.19, no.10, pp.727-736.

@article{article, author={SEDA KAHRAMAN Et Al. }, title={Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer}, journal={Future oncology (London, England)}, year=2023, pages={727-736} }